Abstract
INTRODUCTION
Chronic obstructive pulmonary disease (COPD), characterized by progressive expiratory aiflow limitation, is a major cause of chronic morbidity and mortality worldwide. 1 According to the World Health Organization (WHO), 2 the total number of deaths from COPD in the world are projected to increase by 30% in the next 10 years; by 2030, COPD would become the fourth leading cause of death worldwide. Among all the major chronic diseases, COPD is the only disease that shows a rising mortality. These increases are mainly linked to the epidemic of tobacco exposure and the indoor and outdoor air pollution in Asian countries. The goals of treatment for COPD are to control acute attack and improve pulmonary function, prevent serious long-term consequences of pulmonary heart disease and respiratory failure. Treatment for patients in stable phase is very important to the fate of COPD. In China, Traditional Chinese Medicine (TCM), as an auxiliary therapy to Western Medicine (WM), was extensively employed for the treatment of stable COPD. In our clinic, it was found that patients with COPD had damage to the spleen functions. Accordingly, Jianpi prescription was chosen as it strengthens body resistance through strengthening the spleen. So, Jianpi therapy became one of the main methods in TCM for stable COPD. In parallel with the Jianpi therapy, a series of studies were conducted to evaluate the effectiveness of Jianpi auxiliary therapy in WM, Jianpi therapy versus WM alone and placebo. To date, some of the randomized controlled trials have investigated the beneficial effects of Jianpi auxiliary therapy in WM and the Jianpi therapy alone in improvement of the clinical symptoms, and the pulmonary function in stable COPD. However, the results were inconsistent due to different in study design and outcome measures. So, we conducted a meta-analysis using updated literature searches to asses the effects and to determine whether Jianpi auxiliary therapy in WM or Jianpi therapy alone were more efficacious than WM alone/placebo in improving the clinical symptoms, increasing lung function, increasing quality of life, and improving the other clinical outcomes.
METHODS
Truly or quasi-randomized controlled trials (RCTs) of TCM for COPD were included, regardless of whether the intervention was blinded to the patients, clinicians or researchers after randomization was done. Trials compared WM with TCM in the control arm were also included. Trials using animals or their processed products were excluded. All eligible literature was included regardless of language. In accordance with our main purpose outlined above, the trials that used TCM in both the treatment and control groups were excluded, as well as the trials that did not report diagnostic criteria. Figure 1 shows the flowchart of the present systematic review.
Literature search
Literature search was performed using PubMed (1990-December 2010), in English by 2 reviewers (Juhong Zhang and Zhen Gao) and using Chinese National Knowledge Infrastructure (CNKI) (1990-December 2010), Chinese Biomedical Database (1990-December 2010), Wangfang Database (1990-December 2010), and VIP Database in Chinese by 2 reviewers (Juhong Zhang and Zhen Gao). Key words used in the search were Chronic Obstructive Lung Disease, COPD, Jianpi (means invigorating the spleen, strengthening the spleen, or nourishing the spleen). Various combinations of the search terms were used depending on the database searched. The type of publication searched was clinical study. Two reviewers for the English literature and Chinese literature worked independently for inclusion. Any disagreements were resolved through discussion.
Data extraction
For the included studies, data were extracted by 2 reviewers (Juhong Zhang and Zhen Gao). Once completed, any disagreements on data extraction and study evaluation were resolved through discussion. The data included study design, patient characteristics, and medication use.
Data analysis
Data were analyzed using Revman 5.0 downloaded from the website of Cochrane collaboration. Meta-analysis was performed for the data. The dichotomous data were expressed as odds ratio (OR) with corresponding 95% confidence interval (95%CI). For continuous data, standardized mean difference (SMD) and 95% CI were calculated. Heterogeneity was tested by χ 2 test. The comparison (Figure 2-4 ) was split into two parts: first comparing TCM with WM, and second comparing TCM plus WM to WM alone. Although the constituents of the compounds were different in each investigation, the whole compounds of TCM should have the following benefits of nourishing Qi and kidney, strengthening spleen and lung. A process was designed to combine across studies to perform a meta-analysis. If the main effects of the whole compound in the studies were similar, the data was combined. The fixed-effect mode was used to combine dichotomous data if homogeneity was found. If heterogeneity was found, the random effect mode was alternatively used. To make the meta-analysis more clinically meaningful, publication bias would be examined by the funnel plot.
RESULTS

Identified studies and characteristics
The English-and Chinese-language literature search yielded a total of 263 published studies, of which the abstracts were reviewed, and then 188 studies were excluded because lack of the controls. The 75 RCTs that were potentially relevant were further reviewed, of which 56 were excluded, 29 because of the duplicate publications, 12 because of comparing between different Chinese medicines, 15 because of pseudorandom and nonrandomized. Finally, 19 RCTs or quasi-RCTs that met the inclusion criteria were included. A total of 1587 subjects in 19 RCTs with a diagnosis of stable COPD were included (Table 1) . However, only 1496 subjects in 17 RCTs were included in Meta analysis (2 RCTs were excluded because of poor quality, but included in the systematic review) ( Figure 1 ). Table 2 shows the methodologic qualities of trials. Of the 19 RCTs, 
Quality assessment
Meta-analysis
In meta-analysis, we only analysed the ending indexes which had no significant heterogeneity. 12 studies compared TCM with WM were included in meta-analysis. Since they nourished the spleen, we combined data across 12 studies. Notably, the meta-analysis of high-quality trials demonstrated that there was significant difference in cure rate between TCM-WM group and WM group [ (Figure 3 ). Between TCM group and placebo group, only FVC was significantly improved in TCM group [total SMD= 0.54, 95% CI (0.27, 0.81), P<0.0001]. However, no significant difference was found in other parameters of pulmonary function (FEV1and FEV1/FVC) between the two groups (P>0.05) (Figure 4) . Because of significant heterogeneity, some parameters of the trials were not included in meta-analysis. Table 3 shows the outcome end-points which were not included in meta-analysis but reported in RCTs. The funnel plot ( Figure 5) shows that there was significant publication bias in effective rate. With fewer than five trials to compare, we did not examine publication bias of the other ending indexes in meta-analysis.
DISCUSSION
To date, using the bronchodilator and inhaled steroids for patients with COPD remains controversial. Bronchodilator has a modest effect on improving lung function. Steroids inhaled are given only for the patients with more severe airway obstruction and frequent exac- erbations.
1
Treatment with the combined use of inhaled steroids and long-acting bronchodilators improves the lung function, clinical symptoms and quality of life as compared with the placebo treatment, but the reports on its effects compared with its mono-components are conflicting. 22, 23 The combination therapy reduces sputum neutrophil percentage, sputum eosinophil counts, and biopsy CD8 lymphocytes in stable COPD. 24 Despite the modest beneficial effects, withdrawal of inhaled steroids may result in deterioration to lung function. So, TCM is an ideal therapeutic method to make up this shortcoming. Many trials show that TCM can improve patients' pulmonary function and quality of life. In the present study, we summarized the results of the findings from 17 RCTs using meta-analysis; 2 RCTs were included in the systematic review, but they were excluded from meta-analysis because of poor quality. There is no convincing evidence to support that Jianpi auxiliary therapy as well as WM/Jianpi therapy could significantly improve effective rate and pulmonary function. However, the treatment of COPD with a combination of Chinese and Western medicine could improve effective rate, pulmonary function and quality of life, as compared with the findings from Zhou et al's study. 25 The traditional Western Medicine treatment of COPD are using bronchodilators and anti-inflammatory. Generally, we should not consider that in the treatment of COPD, WM is effective or not. And we can evaluate the short-term or long-term efficacy of bronchodilator asthma medications or anti-inflammatory treatment for COPD. One systematic review about TCM treatment of COPD in stable phase has been reported, 25 but the treatment is TCM not the Jianpi therapy only. If we don't make this systematic review, those who don't know much about TCM may say TCM is a method that may be useful for COPD. But TCM is not a method, just like WM, it include many different methods, some methods may be useful for COPD, and some may not. So, if you put all the methods together to do the evaluation, it may be hard to evaluate the effect of TCM. In TCM, Lung belongs to "metal", and Spleen belongs to "soil". TCM holds that "soil can transform into metal". That is to say, "soil (spleen)" is the mother of "metal (lung)", and the "mother organ (spleen)" can supply some essence to "son organ (lung)", just like the land can provide nutrients to plants. If the "son organ (lung) " is becoming weak, it will overuse the essence that the "mother organ (spleen)" supply; and in order to meet the "son organ (lung)"'s need, the "mother organ (spleen)" will sooner or later become weak too, then it can not give enough essence, so the "son organ (lung)" will become weaker and weaker. It is also considered in TCM that the spleen is the basis of acquired constitution. Above all, Jianpi therapy is one of the important methods of TCM for treating chronic lung diseases, but whether Jianpi therapy is useful or not for treating COPD in sable phase is still lack of systematic evaluation. Therefore, we conducted this systematic review to evaluate Jianpi therapy of TCM for treating COPD in stable phase. In this study, the analyses provided clear evidence to support the notion that the TCM-WM treatments might be more efficient in effective rate, quality of life, FVC, than WM treatment alone. But for FEV1 and FEV1/FVC, no matter TCM-WM treatment compared with WM treatment alone or TCM treatments compared with placebo, there was no significant difference. The present results were partly consistent with the results from a previously published meta-analysis. 25 Our results suggest that the adjunctive treatment of TCM could significantly improve the patients' quality of life, but this maybe just change the patients' feeling, not really improve the patients' pulmonary function. Quality of life was improved significantly in TCM-WM group (P<0.0001), but no significant difference was found in other parameters of pulmonary function (FEV1 and FEV1/FVC) between the two groups (P>0.05). There was no doubt that TCM can significantly improve effective rate, how well such effects could be translated into clinical outcomes were unknown. This aspect of benefits warrants further investigation. The results of this study should be considered within Table 3 The outcome end-points which were not included in mata-analysis reported in RCTs tion, and no RCT report the outcomes of high-resolution RCT. Third, the variation in treatment regimens, particularly the wide range of TCM in dose, certain herbs, route of administration, and duration of therapy, became a major obstacle to a clear interpretation of the results. Last, we examine the publication bias with a funnel plot, publication bias may exist in trials. The experience in TCM-WM treatment of COPD in stable phase was encouraging. The current evidence shows that the integrated traditional and Western Medicine tends to relieve the symptoms and improve quality of life for patients with stable COPD without obvious adverse reactions. Due to the low methodological quality of trials included, more RCTs of high quality in large scale are required.
